Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| XA1202 | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Janssen Research & Development, LLC | INDUSTRY |
| RTI Health Solutions | OTHER |
Not provided
Not provided
Not provided
Not provided
This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Survey to measure physician awareness and understanding of the key messages in the prescriber guide. |
| |
| Group 2 | Survey to measure patient awareness and understanding of the key messages in the patient card. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | Behavioral | Survey to measure physician awareness and understanding of the key messages in the prescriber guide. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaire | Up to 18 months | |
| Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaire | Up to 18 months |
Not provided
Not provided
- Inclusion criteria:
Physician eligibility:
Patient eligibility:
Not provided
Not provided
Not provided
Physicians of various specialties; patients treated in primary care and specilized clinical practices.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Multiple Locations | France | |||||
Not provided
| ID | Term |
|---|---|
| D000069552 | Rivaroxaban |
| ID | Term |
|---|---|
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D009025 | Morpholines |
Not provided
Not provided
Not provided
Not provided
Not provided
| Rivaroxaban (Xarelto, BAY59-7939) | Behavioral | Survey to measure patient awareness and understanding of the key messages in the patient card. |
|
| Multiple Locations |
| Germany |
| Multiple Locations | Spain |
| Multiple Locations | United Kingdom |
| D010078 |
| Oxazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |